People who used certain 30-mg, 60-mg or 90-mg NP Thyroid tablets made by Acella Pharmaceuticals may be affected by a recall announced in 2020 because testing found some lots contained more thyroid hormone than labeled. The safety consequence was possible overexposure to liothyronine, or T3; the financial consequence is less clear because the supplied notices do not verify a refund, replacement payment or claim deadline. The next step is to review the official FDA notice, contact a pharmacist or prescribing clinician before changing treatment, and confirm whether any medication on hand matches an affected lot.
The first point to establish is timing. The FDA page supplied for this report is dated May 22, 2020, and explicitly says the recall has been completed and terminated. That means readers should not assume that every NP Thyroid product currently in circulation is recalled or that a new 2026 consumer deadline exists.
What the FDA notice confirms
Acella announced a voluntary nationwide recall to the consumer level involving 13 lots of NP Thyroid thyroid tablets in 30-mg, 60-mg and 90-mg strengths. The FDA describes the reason as “super potency.” According to the agency’s summary of the company announcement, testing found that the affected lots could contain up to 115.0% of the labeled amount of liothyronine, also known as T3.
NP Thyroid contains levothyroxine and liothyronine and is used to treat hypothyroidism, according to the FDA notice. The agency warned that people receiving superpotent tablets could experience signs and symptoms associated with hyperthyroidism, or an overactive thyroid. The listed potential effects include weight loss, heat intolerance, fatigue, muscle weakness, hypertension, chest pain, rapid heart rate and heart-rhythm disturbances.
The FDA also identified a higher-stakes concern for pregnant patients: exposure to superpotent NP Thyroid could contribute to negative maternal and fetal outcomes, including miscarriage or impaired fetal development. The notice says Acella had received two adverse-event reports known to be related to the recall at the time of the announcement.
What patients should do with medication on hand
Do not stop prescribed thyroid medication on your own based only on a headline. The FDA specifically advised patients to speak with a health care professional before stopping NP Thyroid. A pharmacist or prescriber can help determine whether the product is from an affected lot and explain a safe treatment decision.
Keep the bottle, package, label and pharmacy records if they are available. Those details may be needed to verify the product and lot. The FDA page supplied here confirms that 13 lots were recalled, but the evidence text does not include the individual lot numbers. Without those identifiers, it would be unsafe to label a particular bottle affected from the supplied material alone.
Patients who develop severe or concerning symptoms such as chest pain, a rapid or irregular heartbeat, or other urgent symptoms should seek prompt medical attention. This is a safety precaution based on the FDA’s listed risks, not a diagnosis of the cause of any symptom.
There is no verified refund route in the evidence
Consumers often look for a replacement, reimbursement or disposal instruction after a drug recall. In this case, the supplied FDA summary does not state a refund amount, compensation program, pharmacy reimbursement policy, disposal deadline or official claim form. It also does not establish that a person who took the medicine is entitled to payment.
That distinction matters because a completed recall is not the same as a settlement or refund program. A reader should not pay a third party to file a claim or assume that filing paperwork will produce money when no administrator, court document or company payment process has been identified. The practical financial step is to ask the dispensing pharmacy, insurer or manufacturer about any transaction-specific replacement or reimbursement policy, while recognizing that those options are not verified by the supplied evidence.
Why the 2026 reports need careful reading
The evidence pack also includes a Fox Business report published August 25, 2026, with a headline describing a nationwide thyroid-medication recall, and an AARP report published July 28, 2026, about a thyroid medication potency issue. The supplied excerpts do not provide enough product identifiers, lot numbers or official recall language to show that either report concerns a new NP Thyroid recall or the same Acella action from 2020.
That is the central evidence boundary: the FDA notice supports the older NP Thyroid recall, but it does not, from the supplied text, verify a new 2026 deadline or a newly affected population. Until a direct FDA or manufacturer notice supplies those details, readers should avoid discarding medication, stopping treatment or expecting a refund solely because of the newer headlines.
The most useful next milestone is a product-specific official notice naming the medicine, strength, lot numbers, distribution scope and consumer instructions. Until then, verify the label with a pharmacist or clinician and use the FDA notice to understand the documented 2020 event rather than treating an unverified newer report as proof of a current recall.
The verified consumer action is narrower than the newer headlines suggest. The FDA documents a completed 2020 Acella recall involving 13 NP Thyroid lots and excess T3, with possible hyperthyroidism-related risks. It does not, in the supplied material, identify a current 2026 NP Thyroid recall, list new lots or create a refund program. Readers should preserve product information, ask a pharmacist or prescriber to verify any bottle, and wait for a direct FDA or manufacturer notice before treating the newer reports as proof of a current affected product.
Sources and methodology
- Thyroid medication recalled nationwide after tablets found to be 'superpotent': FDA - Fox Business - https://www.foxbusiness.com/lifestyle/thyroid-medication-recalled-nationwide-tablets-superpotent-fda
- Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall ... - FDA - https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/acella-pharmaceuticals-llc-issues-voluntary-nationwide-recall-certain-lots-np-thyroidr-thyroid
- Thyroid Medication Recalled Due to Potency Issue - AARP - https://www.aarp.org/health/conditions-treatments/evothyroxine-thyroid-medication-recall-july-2026
- Thyroid tablets recalled nationwide over potential 'superpotency': FDA - https://newsnationnow.com/us-news/recalls/thyroid-tablets-recalled-nationwide-superpotency-fda
